Vasiliki Zolota

Prof. Dr. Vasiliki Zolota

Department of Pathology, Medical School, University of Patras

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
IGIoanna Maria Grypari
Ioanna Maria Grypari
Vasiliki ZolotaVasiliki Zolota
Vasiliki Zolota
VTVasiliki Tzelepi
Vasiliki Tzelepi
Prostate cancer is the second most common malignancy in men, and prostatectomy is the treatment of choice for most patients with at least low risk of progression. The presence of positive margins in the radical prostatectomy specimen is considered an adverse pathologic feature, and may prompt additional therapeutic intervention in the patients. The absence of a distinct capsule around the prostate and intraoperative manipulations that aim to minimize postoperative adverse effects, complicate its wide removal. Proper handling of the specimen during the gross processing is essential for accurate determination of the status of margins or resection. Positive margins, defined as the presence of neoplastic glands in the highlighted-with-ink margin of resection, range from 6–38%. The surgical technique, surgeon’s expertise and tumor (i.e., grade and stage) and patients’ (i.e., BMI) characteristics affect the rate of margin positivity. Extensive or multifocal and nonanterior/nonapical positive margins are linked with higher recurrence rates, especially in organ-confined disease, underscoring the need for treating these patients more aggressively. In summary, detailed description of the status of the margins should be performed in every pathology report to determine patients’ prognosis and the most appropriate therapeutic plan.

9 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Vasiliki ZolotaVasiliki Zolota
Vasiliki Zolota
VTVasiliki Tzelepi
Vasiliki Tzelepi
Zoi PiperigkouZoi Piperigkou
Zoi Piperigkou
HKHelen (Eleni) Kourea
Helen (Eleni) Kourea
EPEfthymia Papakonstantinou
Efthymia Papakonstantinou
Nikos KaramanosNikos Karamanos
Nikos Karamanos
Triple-negative breast cancer (TNBC) is an aggressive subgroup of breast cancer characterized by genomic complexity and therapeutic options limited to only standard chemotherapy. Although it has been suggested that stratifying TNBC patients by pathway-specific molecular alterations may predict benefit from specific therapeutic agents, application in routine clinical practice has not yet been established. There is a growing body of the literature supporting that epigenetic modifications comprised by DNA methylation, chromatin remodeling and non-coding RNAs play a fundamental role in TNBC pathogenesis. Extracellular matrix (ECM) is a highly dynamic 3D network of macromolecules with structural and cellular regulatory roles. Alterations in the expression of ECM components result in uncontrolled matrix remodeling, thus affecting its ability to regulate vital functions of cancer cells, including proliferation, migration, adhesion, invasion and epithelial-to-mesenchymal transition (EMT). Recent molecular data highlight the major role of tumor microenvironment and ECM alterations in TNBC and approaches for targeting tumor microenvironment have recently been recognized as potential therapeutic strategies. Notably, many of the ECM/EMT modifications in cancer are largely driven by epigenetic events, highlighting the pleiotropic effects of the epigenetic network in TNBC. This article presents and critically discusses the current knowledge on the epigenetic alterations correlated with TNBC pathogenesis, with emphasis on those associated with ECM/EMT modifications, their prognostic and predictive value and their use as therapeutic targets.

9 May 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
VAValsamo K Anagnostou
Valsamo K Anagnostou
FLFrank J Lowery
Frank J Lowery
Vasiliki ZolotaVasiliki Zolota
Vasiliki Zolota
VTVasiliki Tzelepi
Vasiliki Tzelepi
AGArun Gopinath
Arun Gopinath
KSKonstantinos N Syrigos
Konstantinos N Syrigos
Bcl-2 promotes cell survival by inhibiting adapters needed for the activation and cleavage of caspases thus blocking the proteolytic cascade that ultimately dismantles the cell. Bcl-2 has been investigated as a prognostic factor in non small cell lung cancer (NSCLC) patients with conflicting results.

26 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EPEfthymia Papakonstantinou
Efthymia Papakonstantinou
Zoi PiperigkouZoi Piperigkou
Zoi Piperigkou
Nikos KaramanosNikos Karamanos
Nikos Karamanos
Vasiliki ZolotaVasiliki Zolota
Vasiliki Zolota
Obesity is a remarkably important factor for breast carcinogenesis and aggressiveness. The implication of increased BMI in triple negative breast cancer (TNBC) development is also well established. A malignancy-promoting role of the adipose tissue has been supposed, where the adipocytes that constitute the majority of stromal cells release pro-inflammatory cytokines and growth factors. Alterations in adipokines and their receptors play significant roles in breast cancer initiation, progression, metastasis, and drug response. Classic adipokines, such as leptin, adiponectin, and resistin, have been extensively studied in breast cancer and connected with breast cancer risk and progression. Notably, new molecules are constantly being discovered and the list is continuously growing. Additionally, substantial progress has been made concerning their differential expression in association with clinical and pathological parameters of tumors and the prognostic and predictive value of their dysregulation in breast cancer carcinogenesis. However, evidence regarding the mechanisms by which adipose tissue is involved in the development of TNBC is lacking. In the present article we comment on current data on the suggested involvement of these mediators in breast cancer development and progression, with particular emphasis on TNBC, to draw attention to the design of novel targeted therapies and biomarkers.

1 February 2008 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
IMIoannis Maroulis
Ioannis Maroulis
CSCharalambos Spyropoulos
Charalambos Spyropoulos
Vasiliki ZolotaVasiliki Zolota
Vasiliki Zolota
ETEvaggelos Tzorakoleftherakis
Evaggelos Tzorakoleftherakis
Introduction: The incidence of tuberculosis is rising worldwide and rare manifestations of the past are seen more often nowadays. Mammary tuberculosis is a rare clinical entity, often mimicking breast cancer or abscesses of benign or malignant origin. Clinical awareness is necessary during diagnostic work-up for establishing the correct diagnosis and treatment.Case presentation: We present a case of breast tuberculosis diagnosed in a 73 year old woman at our institution. The patient presented with a palpable mass of the right breast with clinical, laboratory and mammographic findings indicative of breast carcinoma. The patient underwent lumpectomy and sentinel lymph node biopsy. Frozen section of the tumor and the sentinel node revealed "granulomatous inflammation", while gross examination confirmed the diagnosis of tuberculous mastitis. The patient received anti-tuberculosis therapy for six months with no side effects or any further complications.Conclusion: Breast tuberculosis is an obscure disease often mistaken for carcinoma or pyogenic abscess of the breast, especially if well-defined clinical features are absent. A high index of suspicion is required because the disease can usually be treated conservatively with current antituberculous modalities while surgical intervention is reserved for rare cases only.

1 April 2007 in Pathology - Research and Practice
Verified
Journal Article
Closed access
Vasiliki ZolotaVasiliki Zolota
Vasiliki Zolota
CSChaido Sirinian
Chaido Sirinian
MMMaria Melachrinou
Maria Melachrinou
Argiris SymeonidisArgiris Symeonidis
Argiris Symeonidis
DBDionysios S Bonikos
Dionysios S Bonikos